[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354232-105":59,"doc-detail-354232-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","development-and-temporal-validation-of-1-2-and-3-year-survival-prediction-models-for-hepatocellular-carcinoma-using-the-seer-database","Development and temporal validation of 1-, 2-, and 3-year survival prediction models for hepatocellular carcinoma using the SEER database","","Hepatocellular carcinoma (HCC) shows substantial variability in survival, while commonly used staging systems and existing prognostic models often fail to capture individual heterogeneity and temporal robustness. Using Surveillance, Epidemiology, and End Results (SEER) data, multi-timepoint Cox models were developed and temporally validated to predict 1-, 2-, and 3-year overall survival. Independent temporal validation used patients diagnosed in 2016–2017, yielding strong discrimination, good calibration, and decision-curve–supported clinical benefit. ",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/development-and-temporal-validation-of-1-2-and-3-year-survival-prediction-models-for-hepatocellular-carcinoma-using-the-seer-database/354232/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/development-and-temporal-validation-of-1-2-and-3-year-survival-prediction-models-for-hepatocellular-carcinoma-using-the-seer-database/354232.png","ImageObject",300,407,{"name":92,"@type":93},"Stanford","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-06","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are existing HCC staging systems and prognostic models insufficient?","Question",{"text":112,"@type":113},"They often inadequately represent biological and clinical heterogeneity, rely on limited cohorts, provide predictions at only one timepoint, and may lack temporal or external validation.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were the survival prediction models developed and validated?",{"text":117,"@type":113},"Models were built using SEER data with a temporal split: cases diagnosed from 2018–2022 for development and internal testing, and cases from 2016–2017 for independent temporal validation.",{"name":119,"@type":110,"acceptedAnswer":120},"Which factors were identified as independent prognostic variables and included in the nomogram?",{"text":121,"@type":113},"Age, alpha-fetoprotein (AFP) level, fibrosis status, AJCC stage, and surgical treatment were identified and incorporated into a multi-timepoint nomogram.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},354232,1790485403,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},2336477552062,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nDevelopment and temporal validation of 1-, 2-, and 3-year survival prediction models for hepatocellular carcinoma using the SEER database  \nZixuan Fu1, Keru Hou2, Yaowu Zhao1, Zhouyan Wang1, Yuhao Qiu1, Qingyuan Yao1 & Ping Huang1􀀍  \nHepatocellular carcinoma (HCC) accounts for most primary liver cancers and displays substantial variability in survival outcomes. Existing staging systems, such as the American Joint Committee on Cancer (AJCC), Barcelona Clinic Liver Cancer (BCLC), and China Liver Cancer Staging (CNLC) systems, often fail to capture individual heterogeneity. Additionally, many published prognostic models rely on small cohorts, predict survival at only a single timepoint, or lack temporal or external validation. Using data from the Surveillance, Epidemiology, and End Results (SEER) Program, we developed and temporally validated multi-timepoint Cox models to predict 1-, 2-, and 3-year overall survival in HCC. Atotal of 3850 patients diagnosed between 2018 and 2022 were included for model development and internal testing, and 2268 patients diagnosed in 2016–2017 formed an independent temporal validation cohort. Age, alpha-fetoprotein (AFP) level, fibrosis status, AJCC stage, and surgical treatment were identified as independent prognostic factors and incorporated into a multi-timepoint nomogram. The model achieved C-indices of 0.762, 0.760, and 0.726 in the training, test, and temporal validation cohorts. Time-dependent AUCs at 1, 2, and 3 years were 0.814, 0.801, and 0.780 in the training cohort; 0.824, 0.809, and 0.807 in the test cohort; and 0.794, 0.793, and 0.779 in the temporal validation cohort, demonstrating consistently strong discrimination. Calibration and decision curve analyses confirmed accurate agreement and clinical benefit. These findings indicate that the proposed model provides a robust tool for individualized survival prediction and risk-stratified clinical decisionmaking in HCC.  \nKeywords Hepatocellular carcinoma, SEER program, Survival analysis, Cox proportional hazards models, Nomogram, Risk stratification  \nLiver cancer is a major global health burden, ranking as the sixth most diagnosed malignancy and the third leading cause of cancer-related mortality. In 2022, approximately 870,000 new cases were reported worldwide, and projections indicate that the incidence may nearly double by 2050, exceeding 1.5 million newly diagnosed cases annually1. Hepatocellular carcinoma (HCC), the predominant form of primary liver cancer, accounts for nearly 80% of cases and is strongly associated with chronic hepatitis B or C infection, alcohol misuse, and metabolic disorders2. Due to its asymptomatic onset and high recurrence rate, many patients present at an advanced stage, and survival outcomes vary considerably even among those receiving curative or multimodal treatment3,4. Reliable and interpretable prognostic tools are therefore essential to support individualized clinical decision-making.  \nCommonly used prognostic systems for HCC, including the American Joint Committee on Cancer (AJCC), Barcelona Clinic Liver Cancer (BCLC), and China Liver Cancer Staging (CNLC) systems, are largely based on  \n1Department of Hepatobiliary Surgery, First Affiliated Hospital of Chongqing Medical University, Chongqing, People’s Republic of China. 2Department of Respiratory Medicine, National Clinical Research Center for Children and Adolescents’ Health and Diseases, Ministry of Education Key Laboratory of Child Development and Disorders, Children’s Hospital of Chongqing Medical University, Chongqing, People’s Republic of China. 􀀍 email: [huangping4069@163.com](huangping4069@163.com)  \n[www. nature.com/scientificreports/](www. nature.com/scientificreports/)  \nanatomical tumor burden and hepatic function, and thus have limited ability to capture biological and clinical heterogeneity across patients5–7. Recent advances in statistical modeling, arti","cbCaiddNvT8QioWy","https://ap.wps.com/l/cbCaiddNvT8QioWy","pdf",2305200,11,"English","# Methods\n## Data source\n## Model development and validation\n## Performance evaluation","[{\"question\":\"Why are existing HCC staging systems and prognostic models insufficient?\",\"answer\":\"They often inadequately represent biological and clinical heterogeneity, rely on limited cohorts, provide predictions at only one timepoint, and may lack temporal or external validation.\"},{\"question\":\"How were the survival prediction models developed and validated?\",\"answer\":\"Models were built using SEER data with a temporal split: cases diagnosed from 2018–2022 for development and internal testing, and cases from 2016–2017 for independent temporal validation.\"},{\"question\":\"Which factors were identified as independent prognostic variables and included in the nomogram?\",\"answer\":\"Age, alpha-fetoprotein (AFP) level, fibrosis status, AJCC stage, and surgical treatment were identified and incorporated into a multi-timepoint nomogram.\"}]","Development and temporal validation of 1-, 2-, and 3-year survival prediction models for hepatocellular carcinoma using the SEER database | PDF",1790109676,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/84722be2e9ddcffe8c93a92b0390fb15.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7ac45c98d430137aaed26e3627487ebc.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8d856339c2fb1a2a9efc0789df8a6b3d.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3dd1f9a919c2d8cf4a722152ffc29778.webp",980,1287]